Long-Term Efficacy of Abrocitinib in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE EXTEND

Main Article Content

Amy Paller
Michael Cork
Carsten Flohr
Christine Bangert
Stephan Weidinger
John Nesnas
Saleem Farooqui
Pinaki Biswas
Melissa Watkins
Herwig Koppensteiner


abrocitinib, adolescents, adults, moderate-to-severe atopic dermatitis, long-term efficacy


1. Cibinqo (abrocitinib). Prescribing information. Pfizer Labs; February 2023.

2. Cibinqo (abrocitinib) 100 mg film-coated tablets. Summary of product characteristics.
Pfizer Ltd.; March 10, 2023.

3. Simpson EL et al. Lancet. 2020;396:255-266.

4. Silverberg JI et al. JAMA Dermatol. 2020;156:863-873.

5. Bieber T et al. N Engl J Med. 2021;384:1101-1112.

6. Eichenfield LF et al. JAMA Dermatol. 2021;157:1165-1173.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 > >>